HRP20180524T1 - Derivati tipa azaindazola ili diazaindazola kao lijek - Google Patents
Derivati tipa azaindazola ili diazaindazola kao lijek Download PDFInfo
- Publication number
- HRP20180524T1 HRP20180524T1 HRP20180524TT HRP20180524T HRP20180524T1 HR P20180524 T1 HRP20180524 T1 HR P20180524T1 HR P20180524T T HRP20180524T T HR P20180524TT HR P20180524 T HRP20180524 T HR P20180524T HR P20180524 T1 HRP20180524 T1 HR P20180524T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- image
- compound according
- compound
- groups
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 4
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 title 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical class C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910020008 S(O) Inorganic materials 0.000 claims 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 claims 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 102000001332 SRC Human genes 0.000 claims 2
- 108060006706 SRC Proteins 0.000 claims 2
- 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 235000019256 formaldehyde Nutrition 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Claims (18)
1. Spoj sljedeće opće formule (I):
[image]
(I)
ili njegova farmaceutski prihvatljiva sol ili solvat, njegov tautomer, ili stereoizomer ili smjesa njegovih stereoizomera u bilo kojim omjerima, kao što je smjesa enantiomera, posebno racemična smjesa,
pri čemu:
- Y1 i Y4 svaki predstavlja, neovisno jedan od drugoga, skupinu CH ili dušikov atom,
- Y2 predstavlja skupinu C-X-Ar te Y3 predstavlja dušikov atom ili skupinu C-W, ili Y2 predstavlja dušikov atom ili skupinu CH te Y3 predstavlja skupinu C-X-Ar,
uz uvjet da:
▪ najmanje jedan a najviše dvije od skupina Y1, Y2, Y3 i Y4 predstavljaju dušikov atom, te
▪ Y2 i Y4 ne mogu istodobno predstavljati dušikov atom,
- Ar predstavlja arilnu ili heteroarilnu skupinu koja može biti supstituirana s jednom ili više skupina odabranih od atoma halogena, (C1-C6)alkil, (C1-C6)halogenalkil, (C1-C6)halogenalkoksi, (C1-C6)halogentioalkoksi, CN, NO2, OR11, SR12, NR13R14, CO2R15, CONR16R17, SO2R18, SO2NR19R20, COR21, NR22COR23, NR24SO2R25, te R26NR27R28 i/ili može biti fuzionirani heterociklil,
- X predstavlja dvovalentnu skupinu odabranu od O, S, S(O), S(O)2, NR4, S(NR4), S(O)(NR4), S(O)2(NR4), NR4S, NR4S(O), NR4S(O)2, CH2, CH2S, CH2S(O), CH2S(O)2, SCH2, S(O)CH2, S(O)2CH2, CH2CH2, CH=CH, C≡C, CH2O, OCH2, NR4CH2, te CH2NR4,
- W predstavlja skupine R5, SR5, OR5 ili NR5R6,
- U predstavlja skupine CH2 ili NH,
- V predstavlja C(O),
- n predstavlja 0,
- R1 predstavlja vodikov atom, ili skupinu NR7R8,
- R2 predstavlja jednu od sljedećih skupina: NH2, NH(CH2)3NMe2, NMe(CH2)3NMe2, NO2,
[image]
,
ili
[image]
,
- R3 predstavlja H,
- R4, R11 do R25 te R27 do R28 svaki predstavlja, neovisno jedan od drugoga, vodikov atom ili (C1-C6)alkilnu skupinu,
- R5 i R6 svaki predstavlja, neovisno jedan od drugoga, vodikov atom ili (C1-C6)alkilnu skupinu, koja može biti supstituirana arilnom skupinom ili može biti supstituirana benzilnom skupinom,
- R7 i R8 svaki predstavlja, neovisno jedan od drugoga, vodikov atom ili koji može biti supstituiran (C1-C6)alkilnom skupinom ili (C3-C12)cikloalkilnom skupinom ili može biti supstituiran heterociklilom, te
- R26 predstavlja (C1-C6)alkilnu skupinu.
2. Spoj prema patentnom zahtjevu 1, naznačeno time da
- Y1 i/ili Y4 = N,
- Y2 = CH ili C-X-Ar, te
- Y3 = C-W ili C-X-Ar.
3. Spoj prema bilo patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačeno time da X predstavlja dvovalentnu skupinu odabranu od S, S(O), S(O)2, NR4, CH2, CH2S, CH2S(O), CH2S(O)2, CH2O, CH2NR4, NHS(O)2, SCH2, S(O)CH2, S(O)2CH2, S(O)2NH, OCH2, NR4CH2, CH2CH2, CH=CH, te C≡C; pogotovo od S, S(O), S(O)2, NR4, CH2, SCH2, S(O)CH2, S(O)2CH2, S(O)2NH, CH2CH2, C≡C, OCH2, te NR4CH2, pri čemu je prvi atom tih skupina vezan na atom C lanca C-X-Ar.
4. Spoj prema patentnom zahtjevu 3, naznačeno time da X predstavlja dvovalentnu skupinu odabranu od S, S(O)2, CH2, SCH2, S(O)2CH2, S(O)2NH, CH2CH2, i C≡C, pri čemu je prvi atom tih skupina vezan na atom C lanca C-X-Ar.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time da Ar predstavlja arilnu skupinu, kao što je fenil, koja može biti supstituirana s jednom ili više skupina odabranih od atoma halogena, (C1-C6)alkil, (C1-C6)halogenalkil, (C1-C6)halogenalkoksi, (C1-C6)halogentioalkoksi, CN, NO2, OR11, SR12, NR13R14, CO2R15, CONR16R17, SO2R18, SO2NR19R20, COR21, NR22COR23 i NR24SO2R25; ili skupinu koja je piridin.
6. Spoj prema patentnom zahtjevu 5, naznačeno time da Ar predstavlja skupinu odabranu od sljedećih skupina:
[image]
[image]
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, naznačeno time da W predstavlja skupine R5, SR5, OR5 ili NR5R6, s tim da R5 i R6 predstavljaju, neovisno jedan od drugoga, vodikov atom ili (C1-C6)alkilnu skupinu.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time da R7 predstavlja vodikov atom, a R8 predstavlja (C3-C12)cikloalkilnu skupinu ili koja može biti supstituirana heterociklilom.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, naznačeno time da R1 predstavlja jednu od sljedećih skupina: H,
[image]
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, naznačeno time da je odabran od sljedećih spojeva:
[image]
[image]
[image]
[image]
[image]
[image]
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, za upotrebu kao lijek.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, za upotrebu kao lijek namijenjen liječenju karcinoma, upalnih i neurodegenerativnih bolesti kao što je Alzheimerova bolest, posebice karcinoma.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, za upotrebu kao inhibitor kinaza kao što je ALK, Abl i/ili c-Src.
14. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, za upotrebu kao lijek namijenjen liječenju bolesti povezane s kinazom kao što je ALK, Abl i/ili c-Src.
15. Farmaceutski pripravak koji sadrži najmanje jedan spoj formule (I) prema bilo kojem od patentnih zahtjeva 1 do 10, i najmanje jedan farmaceutski prihvatljiv ekscipijens.
16. Farmaceutski pripravak prema patentnom zahtjevu 15, koji dalje sadrži najmanje jedan drugi aktivni sastojak kao što je antikancerogeno sredstvo.
17. Farmaceutski pripravak koji sadrži:
(i) najmanje jedan spoj formule (I) prema bilo kojem od patentnih zahtjeva 1 do 10, te
(ii) najmanje jedan drugi aktivni sastojak, kao što je antikancerogeno sredstvo,
kao kombinirani proizvod za istodobnu, odvojenu ili sekvencijalnu upotrebu.
18. Metoda priprave spoja formule (I) prema bilo kojem od patentnih zahtjeva 1 do 10, koja obuhvaća sljedeće sukcesivne korake:
(a1) povezivanje između spoja sljedeće formule (A):
[image]
(A)
u kojoj Y1, Y2, Y3 i Y4 jesu kao što je definirano u patentnom zahtjevu 1, te R29 predstavlja vodikov atom ili N-zaštićenu skupinu,
sa spojem sljedeće formule (B):
[image]
(B)
u kojoj R1, R2, U, V i n jesu kao što je definirano u patentnom zahtjevu 1, te R30= OH ili izlazna skupina kao što je Cl, da bi nastao spoj sljedeće formule (C):
[image]
(C)
u kojoj Y1, Y2, Y3, Y4, R1, R2, U, V i n jesu kao što je definirano u patentnom zahtjevu 1, te R29 jest takav kao što je gore definirano,
(b1) moguće uklanjanje zaštitne skupine s dušikova atoma koji nosi R29 skupinu i predstavlja N-zaštićenu skupinu da bi nastao spoj formule (I),
(c1) moguća tvorba soli spoja formule (I) dobivena u prethodnom koraku da bi nastala farmaceutski prihvatljiva sol od istoga.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1150651A FR2970967B1 (fr) | 2011-01-27 | 2011-01-27 | Derives de type azaindazole ou diazaindazole comme medicament |
EP12701884.4A EP2668184B1 (en) | 2011-01-27 | 2012-01-27 | Derivatives of azaindazole or diazaindazole type as medicament |
PCT/EP2012/051283 WO2012101239A1 (en) | 2011-01-27 | 2012-01-27 | Derivatives of azaindazole or diazaindazole type as medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20180524T1 true HRP20180524T1 (hr) | 2018-05-04 |
Family
ID=44318089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180524TT HRP20180524T1 (hr) | 2011-01-27 | 2018-03-29 | Derivati tipa azaindazola ili diazaindazola kao lijek |
Country Status (30)
Country | Link |
---|---|
US (2) | US20130172360A1 (hr) |
EP (1) | EP2668184B1 (hr) |
JP (1) | JP5931926B2 (hr) |
KR (2) | KR20180122028A (hr) |
CN (1) | CN103339129B (hr) |
AR (1) | AR084935A1 (hr) |
AU (1) | AU2012210467B2 (hr) |
CA (1) | CA2823824C (hr) |
CY (1) | CY1120088T1 (hr) |
DK (1) | DK2668184T3 (hr) |
ES (1) | ES2661695T3 (hr) |
FR (1) | FR2970967B1 (hr) |
HK (1) | HK1186737A1 (hr) |
HR (1) | HRP20180524T1 (hr) |
HU (1) | HUE037153T2 (hr) |
IL (2) | IL227496B (hr) |
LT (1) | LT2668184T (hr) |
MA (1) | MA34903B1 (hr) |
MX (1) | MX356411B (hr) |
MY (1) | MY180666A (hr) |
PL (1) | PL2668184T3 (hr) |
PT (1) | PT2668184T (hr) |
RS (1) | RS57101B1 (hr) |
RU (1) | RU2600976C2 (hr) |
SI (1) | SI2668184T1 (hr) |
TN (1) | TN2013000293A1 (hr) |
TR (1) | TR201802944T4 (hr) |
TW (1) | TWI546303B (hr) |
UA (1) | UA109698C2 (hr) |
WO (1) | WO2012101239A1 (hr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
EP2817292B1 (en) | 2012-02-22 | 2019-12-18 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
EP2689779A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
WO2014026125A1 (en) * | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EP3233840B1 (en) | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134320A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10211205B2 (en) * | 2016-04-27 | 2019-02-19 | International Business Machines Corporation | Field effect transistor structure for reducing contact resistance |
CN108570052A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
MA52494A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation |
EP3788046A1 (en) | 2018-05-04 | 2021-03-10 | Incyte Corporation | Salts of an fgfr inhibitor |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
EP4045151A1 (en) | 2019-10-14 | 2022-08-24 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
WO2021197467A1 (zh) * | 2020-04-02 | 2021-10-07 | 上海华汇拓医药科技有限公司 | 多靶点的抗肿瘤化合物及其制备方法和应用 |
CN116745268A (zh) | 2020-11-20 | 2023-09-12 | 2692372安大略公司 | 苯磺酰胺衍生物及其用途 |
TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為fgfr抑制劑之三環雜環 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199902301T2 (xx) * | 1997-03-19 | 1999-12-21 | Basf Aktiengesellschaft | Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�. |
EP1215208B1 (en) | 1997-10-27 | 2006-07-12 | Agouron Pharmaceuticals, Inc. | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
CN100338047C (zh) | 2000-06-22 | 2007-09-19 | 辉瑞大药厂 | 吡唑并嘧啶酮类的制备方法 |
WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
CA2620254A1 (en) * | 2005-08-25 | 2007-03-01 | F. Hoffmann-La Roche Ag | P38 map kinase inhibitors and methods for using the same |
WO2008010964A1 (en) | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
PL2120932T3 (pl) | 2006-12-20 | 2015-02-27 | Nerviano Medical Sciences Srl | Indazolowe pochodne jako inhibitory kinazy do leczenia raka |
NZ583450A (en) | 2007-07-20 | 2012-05-25 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
ES2630026T3 (es) | 2008-12-18 | 2017-08-17 | Nerviano Medical Sciences S.R.L. | Derivados indazólicos sustituidos activos como inhibidores de cinasa |
FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
-
2011
- 2011-01-27 FR FR1150651A patent/FR2970967B1/fr active Active
-
2012
- 2012-01-20 TW TW101102531A patent/TWI546303B/zh active
- 2012-01-27 KR KR1020187031264A patent/KR20180122028A/ko not_active Application Discontinuation
- 2012-01-27 MY MYPI2013002799A patent/MY180666A/en unknown
- 2012-01-27 KR KR1020137022330A patent/KR101923751B1/ko active IP Right Grant
- 2012-01-27 JP JP2013550886A patent/JP5931926B2/ja active Active
- 2012-01-27 WO PCT/EP2012/051283 patent/WO2012101239A1/en active Application Filing
- 2012-01-27 PL PL12701884T patent/PL2668184T3/pl unknown
- 2012-01-27 CA CA2823824A patent/CA2823824C/en active Active
- 2012-01-27 MX MX2013008673A patent/MX356411B/es active IP Right Grant
- 2012-01-27 PT PT127018844T patent/PT2668184T/pt unknown
- 2012-01-27 DK DK12701884.4T patent/DK2668184T3/en active
- 2012-01-27 LT LTEP12701884.4T patent/LT2668184T/lt unknown
- 2012-01-27 AR ARP120100272A patent/AR084935A1/es active IP Right Grant
- 2012-01-27 RU RU2013138624/04A patent/RU2600976C2/ru active
- 2012-01-27 MA MA36177A patent/MA34903B1/fr unknown
- 2012-01-27 US US13/823,658 patent/US20130172360A1/en not_active Abandoned
- 2012-01-27 CN CN201280006671.8A patent/CN103339129B/zh active Active
- 2012-01-27 ES ES12701884.4T patent/ES2661695T3/es active Active
- 2012-01-27 RS RS20180418A patent/RS57101B1/sr unknown
- 2012-01-27 SI SI201231273T patent/SI2668184T1/en unknown
- 2012-01-27 UA UAA201310425A patent/UA109698C2/ru unknown
- 2012-01-27 AU AU2012210467A patent/AU2012210467B2/en active Active
- 2012-01-27 EP EP12701884.4A patent/EP2668184B1/en active Active
- 2012-01-27 HU HUE12701884A patent/HUE037153T2/hu unknown
- 2012-01-27 TR TR2018/02944T patent/TR201802944T4/tr unknown
- 2012-11-27 US US13/686,334 patent/US8883821B2/en active Active
-
2013
- 2013-07-11 TN TNP2013000293A patent/TN2013000293A1/fr unknown
- 2013-07-16 IL IL227496A patent/IL227496B/en active IP Right Grant
- 2013-12-24 HK HK13114261.8A patent/HK1186737A1/xx unknown
-
2018
- 2018-02-26 IL IL257748A patent/IL257748B/en active IP Right Grant
- 2018-03-26 CY CY20181100338T patent/CY1120088T1/el unknown
- 2018-03-29 HR HRP20180524TT patent/HRP20180524T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180524T1 (hr) | Derivati tipa azaindazola ili diazaindazola kao lijek | |
HRP20170104T1 (hr) | Derivati tipa azaindazola ili diazaindazola za liječenje boli | |
RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
JP2013523614A5 (hr) | ||
RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
JP2014503574A5 (hr) | ||
RU2009105826A (ru) | 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ | |
ES2543645T3 (es) | Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia | |
JP2013512903A5 (hr) | ||
RU2013148922A (ru) | Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства | |
NO991423D0 (no) | Qinolinderivater som inhiberer effekten av vekstfaktorer som VEGF | |
RU2006132071A (ru) | Производные антраниловой кислоты, способы их получения и применение | |
RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
RS54683B1 (en) | HETEROARYL SUBSTITUTED PIROLO [2,3-B] PYRIDINES AND PYROLO [2,3-B] PYRIMIDINES AS JANUS KINASE INHIBITORS | |
JP2014037426A5 (hr) | ||
JP2014500295A5 (hr) | ||
JP2014500296A5 (hr) | ||
RU2011151835A (ru) | Пиразолопиримидины и родственные гетероциклы как ингибиторы киназ | |
RU2014115476A (ru) | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ | |
BR0113057A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para produzir um efeito antiangiogênico e/ou efeito de redução da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento | |
RU2014109748A (ru) | Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor | |
HUP0201722A2 (hu) | Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére | |
RU2011119450A (ru) | Содержащее конденсированную кольцевую структуру производное и его применение в медицине |